Skip to main content
    J

    Janux Therapeutics Inc (JANX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $17.18
    -0.97 (-5.34%)

    Market Cap: $1.05B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(15/21)
    Avg Surprise
    +8.83%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.49
    Range$-0.67 - $-0.04
    14 analysts
    EPS RevisionsNo revisions (7d)
    4
    7
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.52+5.6%
    60d ago$-0.52+5.8%
    30d ago$-0.50+2.3%
    7d ago$-0.490.0%
    Current$-0.49
    Revenue Consensus
    $6M
    Range$0 - $35M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.43
    Range$-0.99 - $0.33
    14 analysts
    Revenue Consensus
    $376220
    Range$-15048210 - $48M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.43---
    Sep 26EST
    		-$-0.49---
    Jun 26
    Reported Aug 6
    		$-0.35$-0.26-34.62%Miss+36.4%
    Mar 26
    Reported May 7
    		$-0.39$-0.52+25.00%Beat-2.6%
    Dec 25
    Reported Feb 26
    		$-0.51$-0.65+21.54%Beat-41.7%
    Sep 25
    Reported Nov 6
    		$-0.39$-0.61+36.07%Beat+23.5%
    Jun 25
    Reported Aug 7
    		$-0.55$-0.48-14.58%Miss-400.0%
    Mar 25
    Reported May 8
    		$-0.38$-0.39+2.56%Beat-26.7%
    Dec 24
    Reported Feb 27
    		$-0.36$-0.43+15.59%Beat-44.0%
    Sep 24
    Reported Nov 6
    		$-0.51$-0.36-41.67%Miss-104.0%
    Jun 24
    Reported Aug 7
    		$-0.11N/A+62.07%Beat+73.8%
    Mar 24
    Reported May 7
    		$-0.30$-0.33+9.09%Beat+28.6%
    Dec 23
    Reported Mar 8
    		$-0.25$-0.39+35.90%Beat+35.9%
    Sep 23
    Reported Nov 7
    		$-0.25$-0.43+41.86%Beat+37.5%
    Jun 23
    Reported Aug 8
    		$-0.42$-0.51+17.65%Beat-2.4%
    Mar 23
    Reported May 9
    		$-0.42$-0.46+8.70%Beat-31.2%
    Dec 22
    Reported Mar 10
    		$-0.39$-0.49+20.41%Beat-18.2%
    Sep 22
    Reported Nov 10
    		$-0.40$-0.53+24.53%Beat-53.8%
    Jun 22
    Reported Aug 9
    		$-0.41$-0.39-5.13%Miss-173.3%
    Mar 22
    Reported May 10
    		$-0.32$-0.37+13.51%Beat+84.2%
    Dec 21
    Reported Mar 18
    		$-0.33$-0.31-6.45%Miss+87.5%
    Sep 21
    Reported Nov 9
    		$-0.26$-0.17-52.94%Miss+88.2%
    Jun 21
    Reported Aug 10
    		$-0.15$-0.16+6.25%Beat-
    Mar 21
    Reported Jun 11
    		$-2.02$0.00N/AMiss-
    Dec 20
    Reported Mar 30
    		$-2.63$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-2.20$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-10.48EV/EBITDAN/A
    Price/FCF-25.79xFCF Yield-3.88%
    Profitability
    Profit Margin0.00%Operating Margin-308.70%
    ROE-10.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio16.35xQuick Ratio16.35x
    Trading Statistics
    Beta2.39Avg Volume960.13K
    52-Week High$35.3452-Week Low$12.12

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.46
    SMA 20$17.09
    SMA 50$17.41
    SMA 200$15.12
    EMA 10$17.55
    EMA 20$17.43
    EMA 50$17.14
    EMA 200$17.11

    MACD

    Line: 0.11Signal: -0.00Hist: 0.11

    ADX

    ADX: 16.2+DI: 24.2-DI: 25.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down48.0
    PSAR$16.65

    Bollinger Bands

    Upper Band$18.43
    Lower Band$15.75
    %B Position1568%(Upper)
    Band Width0.53

    RSI (14-Day)

    Neutral
    48.3

    Momentum Oscillators

    Stoch %K62.9
    Stoch %D74.5
    Williams %R-58.3
    ROC (10d)1.4%
    Momentum0.23
    CCI (20d)46.2
    MFI (14d)53.6

    Volatility Measures

    ATR (14d)$0.89(5.2%)
    StdDev (20d)0.67
    Hist Vol48.2%(High)

    Volume Flow

    VWAP$17.43
    OBV-23.2M
    AD Line-21.8M
    CMF (20d)0.004

    Volume Metrics

    Avg Vol (20d)962.2K
    Vol Ratio0.8x
    VWMA (20d)$17.14

    Pivot Points

    R3$19.16
    R2$18.88
    R1$18.52
    Pivot Point$18.24
    S1$17.87
    S2$17.59
    S3$17.23

    Advanced Oscillators

    TSI3.29
    Ultimate Osc50.7
    KST-14.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$10.27M$3.73M$7.88M$10.00M$0$0$-8,512,000$439,000$8.90M$1.25M$2.46M$2.52M
    Cost of Revenue$0$0$8.94M$0$0$0$20.81M$0$0$0$531,000$0
    Gross Profit$10.27M$3.73M$-1,060,000$10.00M$0$0$-20,806,000$439,000$8.90M$1.25M$2.46M$2.52M
    Operating Expenses$41.96M$37.95M$42.40M$45.25M$45.12M$34.90M$29.02M$36.28M$22.72M$21.41M$18.60M$18.33M
    R&D$30.99M$26.81M$31.55M$34.63M$34.66M$25.05M$20.81M$18.61M$14.90M$14.07M$12.24M$11.89M
    SG&A$10.96M$11.13M$10.85M$10.62M$10.45M$9.84M$8.22M$17.67M$7.82M$7.34M$6.36M$6.44M
    Operating Income$-31,690,000$-34,213,000$-42,401,000$-35,251,000$-45,118,000$-34,897,000$-29,022,000$-35,842,000$-13,822,000$-20,161,000$-16,137,000$-15,813,000
    Interest Income$9.72M$9.85M$10.46M$10.94M$11.26M$11.39M$8.81M$7.78M$7.86M$5.40M$4.38M$4.25M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-21,972,000$-24,361,000$-31,946,000$-24,313,000$-33,858,000$-23,508,000$-20,216,000$-28,059,000$-5,959,000$-14,760,000$-11,758,000$-11,568,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-21,972,000$-24,361,000$-31,946,000$-24,313,000$-33,858,000$-23,508,000$-20,216,000$-28,059,000$-5,959,000$-14,760,000$-11,758,000$-11,568,000
    EBITDA$-34,113,000$-36,368,000$-45,457,000$-39,373,000$-49,783,000$-38,599,000$-31,437,000$-38,230,000$-16,289,000$-21,416,000$-17,667,000$-17,421,000
    EBIT$-31,690,000$-34,213,000$-42,401,000$-35,251,000$-45,118,000$-34,897,000$-29,022,000$-35,842,000$-13,822,000$-20,161,000$-16,137,000$-15,813,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about JANX

    News

    Why (JANX) Price Action Is Critical for Tactical Trading

    This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX) using AI models to provide tactical trading strategies. Key findings indicate strong near- and mid-term sentiment but a weak long-term outlook...

    Stock Traders Daily•10/12/26•Neutral

    Is First Patient Dosed Altering The Investment Case For Janux Therapeutics (JANX)?

    Janux Therapeutics has dosed its first patient in a Phase 1 study combining JANX013 and JANX007 for metastatic castration-resistant prostate cancer...

    Simply Wall Street•10/1/26•Somewhat-Bullish

    Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

    Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for JANX013. This novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific is designed to enhance anti-tumor...

    BioSpace•9/15/26•Bullish

    Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

    Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 clinical trial for JANX013, a novel PSMA-targeted...

    Yahoo Finance Australia•9/14/26•Bullish

    Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate

    Janux Therapeutics has dosed the first participant in its Phase 1 study for a prostate cancer candidate. The company, a clinical-stage biopharmaceutical firm...

    marketscreener.com•9/14/26•Somewhat-Bullish

    JANX Valuation and Fair Value

    P/E
    -10.5x
    P/FCF
    -25.8x
    P/B
    1.2x
    See GNG's fair value

    JANX Profitability: Margins, ROIC and FCF

    Operating margin
    -308.7%
    Net margin
    0.0%
    ROE
    -10.7%
    FCF margin
    -174.7%
    FCF yield
    -3.9%

    JANX Competitors

    CompanyTicker
    Enovis CorpENOV
    CureVac NVCVAC
    Immatics NVIMTX
    Artivion IncAORT
    Replimune Group IncREPL
    HealthStream IncHSTM
    Procept Biorobotics CorpPRCT
    Integra LifeSciences HoldingsIART

    Sector: Healthcare

    JANX Analyst Ratings

    Consensus
    Buy
    Analysts
    18
    Strong Buy
    2
    Buy
    14
    Hold
    1
    Sell
    0
    Strong Sell
    1

    JANX Bull Case vs Bear Case

    Bull case

    • JANX grew quarterly revenue 2178.0% year over year.
    • 88.9% of JANX's analyst ratings are Buy or Strong Buy.

    JANX Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    1.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.49
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 7 down

    Frequently Asked Questions About JANX

    Does JANX pay dividends?

    Janux Therapeutics Inc (JANX) does not currently pay a regular dividend.

    What is JANX's market cap?

    Janux Therapeutics Inc (JANX) has a market capitalization of $1.05B with a current stock price of $17.18.

    Related stocks

    Sector: Healthcare

    All stocks starting with J

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In